AirNet Technology raises $180 million in digital assets offering
AC Immune SA (NASDAQ:ACIU) maintained its Buy rating and $16.00 price target from H.C. Wainwright. This affirmation follows the recent announcement by AC Immune that the Phase 2b ReTain trial for their Alzheimer's disease immunotherapy program, ACI-35.030 (JNJ-2056), has seen a promising prescreening rate. This development has led to a milestone payment from partner JNJ (JNJ; not rated) within the current month.
The ReTain trial focuses on preclinical Alzheimer's disease (AD), a stage where patients do not yet show symptoms. The challenge of screening and enrolling participants for such a trial has been significant.
However, the increased awareness among patients, caregivers, and physicians, spurred by the approval of new anti-Abeta therapies and the recognition of the potential benefits of an anti-tau strategy, has resulted in strong recruitment for the trial.
H.C. Wainwright's decision to maintain the stock's rating and price target is based on these positive developments. The firm's commentary highlights the potential of AC Immune's program in addressing the unmet medical needs within the Alzheimer's disease treatment landscape.
The milestone payment from JNJ marks a significant achievement for AC Immune and underscores the collaborative effort in advancing this promising therapy.
AC Immune's anti-phospho tau active immunotherapy program is designed to target the pathological tau protein, which is associated with the progression of Alzheimer's disease. The success of the ReTain trial's prescreening phase is a positive indicator for the ongoing research and development efforts in the field of neurodegenerative diseases.
Investors and stakeholders in AC Immune SA will continue to monitor the progress of the Phase 2b ReTain trial and the potential impact of ACI-35.030 (JNJ-2056) on the treatment of Alzheimer's disease. The company's partnership with JNJ and the sustained support from H.C. Wainwright suggest confidence in the therapeutic approach and its future prospects.
In other recent news, AC Immune SA has achieved several significant milestones. The Swiss biopharmaceutical company recently received a payment of CHF 24.6 million from Janssen Pharmaceuticals for its Phase 2b ReTain trial for the investigational Alzheimer's treatment, ACI-35.030. This follows a previous payment, bringing the total received to CHF 40 million.
AC Immune's Tau positron emission tomography (PET) diagnostic agent, [18F]PI-2620, received FDA Fast Track Designation for its use in Alzheimer’s disease. The diagnostic agent is currently in Phase 3 clinical development and is designed to detect Tau pathology in Alzheimer's disease.
C Immune has unveiled a novel therapeutic antibody drug conjugate technology, morADC, aimed at treating neurodegenerative diseases. The company has also been recognized by BTIG with a 'Buy' rating, highlighting its extensive pipeline focused on detecting and clearing toxic proteins related to neurodegenerative diseases.
Furthermore, AC Immune has entered into a global option and license agreement with Takeda Pharmaceutical Company (NYSE:TAK) Limited for the development of ACI-24.060, a potential Alzheimer's disease treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.